TY - JOUR

T1 - Experimental infection using mouse-adapted influenza b virus in a mouse model

AU - Prokopyeva, Elena

AU - Kurskaya, Olga

AU - Sobolev, Ivan

AU - Solomatina, Mariia

AU - Murashkina, Tatyana

AU - Suvorova, Anastasia

AU - Alekseev, Alexander

AU - Danilenko, Daria

AU - Komissarov, Andrey

AU - Fadeev, Artem

AU - Ramsay, Edward

AU - Shestopalov, Alexander

AU - Dygai, Alexander

AU - Sharshov, Kirill

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Every year, influenza B viruses (IBVs) contribute to annual illness, and infection can lead to serious respiratory disease among humans. More attention is needed in several areas, such as increasing virulence or pathogenicity of circulating B viruses and developing vaccines against current influenza. Since preclinical trials of anti-influenza drugs are mainly conducted in mice, we developed an appropriate infection model, using an antigenically-relevant IBV strain, for furtherance of anti-influenza drug testing and influenza vaccine protective efficacy analysis. A Victoria lineage (clade 1A) IBV was serially passaged 17 times in BALB/c mice, and adaptive amino acid substitutions were found in hemagglutinin (HA) (T214I) and neuraminidase (NA) (D432N). By electron microscopy, spherical and elliptical IBV forms were noted. Light microscopy showed that mouse-adapted IBVs caused influenza pneumonia on day 6 post inoculation. We evaluated the illness pathogenicity, viral load, and histopathological features of mouse-adapted IBVs and estimated anti-influenza drugs and vaccine efficiency in vitro and in vivo. Assessment of an investigational anti-influenza drug (oseltamivir ethoxysuccinate) and an influenza vaccine (Ultrix®, SPBNIIVS, Saint Petersburg, Russia) showed effectiveness against the mouse-adapted influenza B virus.

AB - Every year, influenza B viruses (IBVs) contribute to annual illness, and infection can lead to serious respiratory disease among humans. More attention is needed in several areas, such as increasing virulence or pathogenicity of circulating B viruses and developing vaccines against current influenza. Since preclinical trials of anti-influenza drugs are mainly conducted in mice, we developed an appropriate infection model, using an antigenically-relevant IBV strain, for furtherance of anti-influenza drug testing and influenza vaccine protective efficacy analysis. A Victoria lineage (clade 1A) IBV was serially passaged 17 times in BALB/c mice, and adaptive amino acid substitutions were found in hemagglutinin (HA) (T214I) and neuraminidase (NA) (D432N). By electron microscopy, spherical and elliptical IBV forms were noted. Light microscopy showed that mouse-adapted IBVs caused influenza pneumonia on day 6 post inoculation. We evaluated the illness pathogenicity, viral load, and histopathological features of mouse-adapted IBVs and estimated anti-influenza drugs and vaccine efficiency in vitro and in vivo. Assessment of an investigational anti-influenza drug (oseltamivir ethoxysuccinate) and an influenza vaccine (Ultrix®, SPBNIIVS, Saint Petersburg, Russia) showed effectiveness against the mouse-adapted influenza B virus.

KW - Amino acid substitutions

KW - Antiviral drugs

KW - Influenza B virus

KW - Influenza model

KW - Influenza vaccine

KW - Mouse-adapted

KW - Pathogenicity

KW - Virulence

KW - influenza vaccine

KW - amino acid substitutions

KW - antiviral drugs

KW - mouse-adapted

KW - influenza model

KW - NEURAMINIDASE

KW - pathogenicity

KW - virulence

KW - influenza B virus

KW - RESISTANCE

UR - http://www.scopus.com/inward/record.url?scp=85083838391&partnerID=8YFLogxK

U2 - 10.3390/v12040470

DO - 10.3390/v12040470

M3 - Article

C2 - 32326238

AN - SCOPUS:85083838391

VL - 12

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 4

M1 - v12040470

ER -